1. Search Result
Search Result
Results for "

resistant tumors

" in MedChemExpress (MCE) Product Catalog:

72

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

1

Peptides

2

Inhibitory Antibodies

15

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156698

    PROTACs Inflammation/Immunology Cancer
    HJM-561 is a potent, selective, orally bioavailable EGFR PROTAC. HJM-561 overcomes osimertinib (HY-15772)-resistant EGFR triple mutations and has anti-tumor activity .
    HJM-561
  • HY-107271

    Others Cancer
    Imperialine 3-β-D-glucoside is the glycoside of Imperialine (HY-N0696). Imperialine 3-β-D-glucoside may exhibit anti-tumor properties against multi-agent resistant tumor cells .
    Imperialine 3-β-D-glucoside
  • HY-160020

    Androgen Receptor Cancer
    ET516 is a potent inhibitor of Androgen Receptor. ET516 significantly inhibits the proliferation and tumor growth of prostate cancer cells expressing AR-resistant mutants .
    ET516
  • HY-P99217

    AMG 102

    c-Met/HGFR Cancer
    Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .
    Rilotumumab
  • HY-117563

    SKI 5C

    SphK Cancer
    CAY10621 (SKI 5C; compound 5c) is a specific sphingosine kinase 1 (SPHK1) inhibitor with an IC50 of 3.3 μM. CAY10621 is low toxic toward cells. CAY10621 has the potential for resistant cancer tumors research .
    CAY10621
  • HY-144070A

    Estrogen Receptor/ERR Cancer
    (Rac)-ErSO-DFP is a derivative of ErSO-DFP and a selective small molecule Erα biomodulator. (Rac)-ErSO-DFP againsts ERα+ breast cancer (including resistant tumors) by hyperactiving the Erα-dependent a-UPR (extracted from patent WO2022087234A1) .
    (Rac)-ErSO-DFP
  • HY-N10765

    Bacterial Inflammation/Immunology Cancer
    Salvinolone is active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Salvinolone shows cytotoxic activity with an IC50 of 47.6 μM against the HL-60 tumor cell line for 72 h .
    Salvinolone
  • HY-N2104

    Others Cancer
    Daurinoline is an alkaloid that can be isolated from the roots of Menispermum dauricum. Daurinoline may be a potential anti-tumor agent or chemosensitizer for chemo-resistant NSCLC research .
    Daurinoline
  • HY-N14106

    Bacterial Infection Cancer
    Cinerubin R has anti-Gram-positive bacteria and inhibition of tumor cell activity, and its inhibition effect on multidrug resistant (MDR) cells is the same as that on protocells .
    Cinerubin R
  • HY-161661

    Others Cancer
    Anticancer agent 223 (Compound V-d) is an anticancer agent that triggers cell death through caspase-dependent and caspase-independent mechanisms. Anticancer agent 223 inhibits tumor spheroid formation and resensitizes cisplatin (HY-17394)-resistant A2780 cells to cisplatin (HY-17394) treatment .
    Anticancer agent 223
  • HY-118138

    DNA Alkylator/Crosslinker Cancer
    NC-182 is an anti-tumor agent and DNA intercalator with a preference for B-form DNA. NC-182 can also promote the unwinding of Z-form DNA to B-form. NC-182 has a potent inhibitory effect on multidrug-resistant and sensitive tumors.
    NC-182
  • HY-139920A

    SH-1028 mesylate

    EGFR Cancer
    Oritinib (SH-1028) mesylate is a selective, orally active, and pyrimidine-based irreversible inhibitor of EGFR with an IC50 of 18 nM. Oritinib (SH-1028) mesylate exhibits potent activity against EGFR sensitive and resistant (T790 M) mutations. Oritinib (SH-1028) mesylate significantly inhibits proliferation of tumor cells with EGFR sensitive and resistant mutation .
    Oritinib mesylate
  • HY-135336A

    (S)-(-)-Verapamil hydrochloride

    P-glycoprotein Leukotriene Receptor Calcium Channel Apoptosis Cancer
    (S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits leukotriene C4 (LTC4) and calcein transport by MRP1. (S)-Verapamil hydrochloride leads to the death of potentially resistant tumor cells .
    (S)-Verapamil hydrochloride
  • HY-N6932

    Cannabinoid Receptor P-glycoprotein Metabolic Disease Cancer
    Voacamine, an indole alkaloid, exhibits potent cannabinoid CB1 receptor antagonistic activity . Voacamine also inhibits P-glycoprotein (P-gp) action in multidrug-resistant tumor cells .
    Voacamine
  • HY-W773183

    Betulonic acid methyl ester; Methyl 3-oxolup-20(29)-en-28-oate

    Others Cancer
    Methyl betulonate (Betulonic acid methyl ester) is a triterpenoid. Methyl betulonate inhibits cell growth of eight tumor (including resistant) and two normal fibroblast cell lines with the IC50s >50.0 μM .
    Methyl betulonate
  • HY-149053

    P-glycoprotein Cancer
    OY-101 is an orally active, potent and specific P-glycoprotein (P-gp) inhibitor. OY-101 can sensitize drug-resistant tumors and effectively reverse tumor multidrug resistance. OY-101 is improvements in water-solubility, cytotoxicity, and reversal activity compared to Tetrandrine (HY-13764) .
    OY-101
  • HY-147812
    POLA1 inhibitor 1
    2 Publications Verification

    DNA/RNA Synthesis Cancer
    POLA1 inhibitor 1 (Compound 12) is an orally active POLA1 inhibitor. POLA1 inhibitor 1 shows antitumor activity against several tumor histotypes and Adarotene-resistant cell line .
    POLA1 inhibitor 1
  • HY-12965B

    TAM Receptor Cancer
    (Z)-S49076 hydrochloride is an orally active inhibitor of MET and AXL that blocks the downstream signaling of these receptors both in vitro and in vivo, inhibiting the proliferation and migration of tumor cells and suppressing tumor growth in xenograft models. (Z)-S49076 hydrochloride is capable of overcoming the resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) due to MET amplification in Erlotinib (HY-50896)-resistant cell lines both in vitro and in vivo. (Z)-S49076 hydrochloride can be used for research in non-small cell lung cancer (NSCLC) .
    (Z)-S49076 hydrochloride
  • HY-127079

    Microtubule/Tubulin Cancer
    Epothilone F is a Microtubule/Tubulin-stabilizing agent with anti-tumor activity. Epothilone F inhibits the proliferation of breast cancer cells, non-small cell lung cancer cells, drug-resistant ovarian cancer cells .
    Epothilone F
  • HY-159935

    Topoisomerase Apoptosis Cancer
    Top1-IN-2 (Compound 1a) is a topoisomerase 1 (Top1) inhibitor. Top1-IN-2 inhibits P-gp resistant tumor cells growth and induces cell apoptosis .
    Top1-IN-2
  • HY-111145

    Androgen Receptor Cancer
    RD162, a diarylthiohydantoin, is an orally active non-steroidal antiandrogen (NSAA). RD162 specifically binds to androgen receptor (AR). RD162 induces tumor regression in mouse models of castration-resistant human prostate cancer .
    RD162
  • HY-19319

    Epigenetic Reader Domain Androgen Receptor Apoptosis Cancer
    MI-136 is an inhibitor of the menin-MLL protein-protein interaction (PPI), with an IC50 of 31 nM and a Kd of 23.6 nM. MI-136 shows to block AR signaling and has the potential for the study in castration-resistant tumors .
    MI-136
  • HY-N2360
    Hinokiflavone
    3 Publications Verification

    E1/E2/E3 Enzyme Apoptosis MMP ClpP Infection Inflammation/Immunology Cancer
    Hinokiflavone is a novel modulator of pre-mRNA splicing activity extracted from plants with anti-inflammatory, anti-tumor and antiviral activities. Hinokiflavone is also a potent inhibitor for matrix metalloproteinases (MMPs). Hinokiflavone attenuates the virulence of Methicillin (HY-121544)-resistant staphylococcus aureus by inhibiting caseinolytic protease P (ClpP) with an IC50 value of 34.36 mg/mL. Hinokiflavone induces apoptosis via the reactive oxygen species-mitochondria-mediated apoptotic pathway and inhibits tumor cell migration and invasion. Hinokiflavone is a SUMO protease inhibitor against sentrin-specific protease 1 (SENP1) activity .
    Hinokiflavone
  • HY-156871

    CaMK Cancer
    CAMK1D-IN-1 (compound I) is an inhibitor of CAMK1D, targeting cytotoxic T lymphocyte (CTL)-resistant tumor cells. CAMK1D impairs CTL-induced death receptor signaling and apoptosis by inhibiting caspases, making it a key and effective target for PD-L1-refractory tumors .
    CAMK1D-IN-1
  • HY-124628
    IPI-9119
    1 Publications Verification

    Fatty Acid Synthase (FASN) Cancer
    IPI-9119 is an orally active, selective and irreversible FASN inhibitor with an IC50 of 0.3 nM in vitro biochemical assay. IPI-9119 inhibits tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse models .
    IPI-9119
  • HY-162040

    P-glycoprotein Cancer
    P-gp inhibitor 17 (compound 2g) is a P-gp inhibitor directly interacted with the transmembrane domain of P-gp. P-gp inhibitor 17 can be used for P-gp-mediated multidrug-resistant in tumor cells study .
    P-gp inhibitor 17
  • HY-110201

    Estrogen Receptor/ERR Cancer
    Estrogen receptor modulator 1 (compound 18) is an orally active and selective estrogen receptor modulator (SERM), with a pIC50 of 0.46. Estrogen receptor modulator 1 induces regression of Tamoxifen-resistant, hormone independent xenograft tumors .
    Estrogen receptor modulator 1
  • HY-N0944

    Others Cancer
    (-)-Heraclenol is a derivative of furocoumarin isolated from Ducrosia anethifolia. (-)-Heraclenol shows antiproliferative and cytotoxic activities on cancer cell lines .
    (-)-Heraclenol
  • HY-173065

    CDK Apoptosis Cancer
    CDK9-IN-36 (Compound T7) is a potent, selective and metabolically stable CDK9 inhibitor with an IC50 value of 1.2 nM. CDK9-IN-36 effectively suppresses cell proliferation, reduces colony formation, and induces apoptosis in Osimertinib (HY-15772)-resistant NSCLC cells by downregulating Mcl-1. CDK9-IN-36 also demonstrates antitumor efficacy in a tumor xenograft model .
    CDK9-IN-36
  • HY-124325

    DNA Alkylator/Crosslinker Cancer
    PIP-199 is a selective inhibitor of RMI (RecQ-mediated genome instability protein) core complex/MM2 interaction, with an IC50 of 36 μM. PIP-199 can be used for the research of sensitizing resistant tumors to DNA crosslinking chemotherapeutics .
    PIP-199
  • HY-106588

    SKI 2053R

    DNA Alkylator/Crosslinker Cancer
    Heptaplatin (SKI 2053R) is a platinum derivative with anticancer activity against various cancer cell lines, including cisplatin-resistant tumor cell lines. SKI-2053R is active in the research of gastric adenocarcinoma and has favorable toxicity profiles .
    Heptaplatin
  • HY-127155

    Bacterial Antibiotic Infection Cancer
    Kigamicin C is an anti-tumor antibiotic that selectively kills pancreatic cancer PANC-1 cells only in nutrient-poor conditions. Kigamicin C has antimicrobial activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) .
    Kigamicin C
  • HY-168492

    Ferroptosis EGFR TrxR Apoptosis Cancer
    TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor. TrxR/EGFR-IN-1 is active against both Gefitinib (HY-50895)-sensitive and resistant lung cancers, effectively inhibiting tumor proliferation and promoting apoptosis. TrxR/EGFR-IN-1 promotes the degradation of GPX4 protein through autophagolysosomal and proteasomal pathways, leading to ferroptosis. In addition, TrxR/EGFR-IN-1 can induce endoplasmic reticulum stress and trigger immunogenic cell death. TrxR/EGFR-IN-1 can be used for the research of Gefitinib (HY-50895)-resistant lung cancer .
    TrxR/EGFR-IN-1
  • HY-135336AS

    (S)-(-)-Verapamil-d7 hydrochloride

    Isotope-Labeled Compounds Leukotriene Receptor Calcium Channel Apoptosis Cancer
    (S)-Verapamil-d7 (hydrochloride) is a deuterium labeled (S)-Verapamil hydrochloride. (S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits leukotriene C4 (LTC4) and calcein transport by MRP1. (S)-Verapamil hydrochloride leads to the death of potentially resistant tumor cells[1][2].
    (S)-Verapamil-d7 hydrochloride
  • HY-161668

    Ligands for E3 Ligase Ferroptosis Cancer
    Ru-Poma is a Ru(II)-based photosensitizer, which attenuates Cisplatin (HY-17394)-resistant tumor through photodynamic therapy (PDT). Ru-Poma photodegrades CRBN through a Pomalidomide (HY-10984) moiety. Ru-Poma induces ferroptosis, through an increase in lipid peroxide, downregulation of GPX4 and GAPDH expression. Ru-Poma exhibits cytotoxicity in A549, with IC50 of 18.46 μM and 0.37 μM in dark and upon irradiation, respectively .
    Ru-Poma
  • HY-162822

    P-glycoprotein Cancer
    P-gp modulator-5 (compound 25) is a modulator of P-gp and can inhibit the proliferation of multidrug resistant (MDR) tumors. P-gp modulator-5 inhibits the activity of drug efflux pumps in MDR cells, leading to a large accumulation of ROS and altered cell cycle profiles .
    P-gp modulator-5
  • HY-170951

    Androgen Receptor Cancer
    AR antagonist 10 (Compound Y5) is potent and orally active androgen receptor (AR) antagonist with an IC50 of 0.04 μM. AR antagonist 10 demonstrates dual mechanisms of action, antagonizes AR by disrupting AR dimerization, and induces AR degradation via the ubiquitin-proteasome pathway. AR antagonist 10 exhibits excellent activity against variant drug-resistant AR mutants. AR antagonist 10 effectively suppresses the tumor growth of the LNCaP xenograft. AR antagonist 10 is potential to be used for drug-resistant prostate cancer .
    AR antagonist 10
  • HY-N14530

    Bacterial Infection Cancer
    Cremeomycin has anti-Gram-positive bacteria activity including methicillin-resistant Staphylococcus aureus (MRSA), MIC is 0.2-0.39 μg/mL. Cremeomycin shows cytotoxicity to mouse tumor cell lines P388, L1210, IMC, S180, B16 and SS3 in vitro .
    Cremeomycin
  • HY-N14144

    Bacterial Infection Cancer
    Cremimycin has anti-Gram-positive bacteria activity including methicillin-resistant Staphylococcus aureus (MRSA), MIC is 0.2-0.39 μg/mL. Cremimycin shows cytotoxicity to mouse tumor cell lines P388, L1210, IMC, S180, B16 and SS3 in vitro .
    Cremimycin
  • HY-N0790
    Lupeol
    3 Publications Verification

    Clerodol; Monogynol B; Fagarasterol

    Androgen Receptor Apoptosis Cancer
    Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen receptor (AR) inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC) .
    Lupeol
  • HY-159580

    STAT Cancer
    STAT3-IN-31 (compound K2071) is a STATtic-derived STAT3 and mitotic inhibitor. STAT3-IN-31 blocks mitotic progression and affects the formation of mitotic spindles. STAT3-IN-31 also affects glioblastoma cell migration and inhibits cell proliferation in tumor spheroids. STAT3-IN-31 is also able to induce glioblastoma senescence, inhibit the growth of Temozolomide (HY-17364)-resistant cells and the secretion of the pro-inflammatory cytokine monocyte chemoattractant protein MCP-1 .
    STAT3-IN-31
  • HY-129236

    Na+/K+ ATPase Apoptosis Cancer
    Hellebrin is a bufadienolide compound extracted from plants that can inhibit tumor cell growth. Hellebrigenin shows potential in overcoming cancer cells' resistance to apoptosis stimuli and has also demonstrated anti-proliferation effects in multidrug-resistant (MDR) cancer cell models. Hellebrin can act on Na+/K+-ATPase to regulate intracellular signaling pathways .
    Hellebrin
  • HY-169903

    Apoptosis Cancer
    SMIP34 is a PELP1 inhibitor. SMIP34 binds to PELP1 with a Kd of 37.4 μM. SMIP34 inhibits cancer cell proliferation and tumor progression. SMIP34 can be used for breast cancer research, and is active against wild-type (WT), mutant (MT) ER + and therapy-resistant (TR)-ER + breast cancer .
    SMIP34
  • HY-12458

    DNA/RNA Synthesis Infection Cancer
    Pyrindamycin A is an antibiotic that inhibits DNA synthesis. Pyrindamycin A shows antitumor activities against murine leukemia, exhibits stronger cytotoxic activities towards murine and human tumor cell lines and especially towards doxorubicin-resistant cells, inhibits P388 and P388/ADR cells with the same IC50 of 3.9 μg/ml .
    Pyrindamycin A
  • HY-13617

    CGP 30694

    Antifolate Cancer
    Edatrexate (CGP 30694), as known as 10-Ethyl-10-deazaaminopterin, is Methotrexate (HY-14519) analog, exhibits antitumor activity against MTX-resistant tumors. Edatrexate is an antifolate antimetabolite, can be used for reasearch of non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and cancer of the head and neck .
    Edatrexate
  • HY-128910

    Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    MC-VC(S)-PABQ-Tubulysin M is a synthetic ADC drug-linker conjugate composed of the tubulin polymerization inhibitor Tubulysin M (an ADC Cytotoxin) (HY-N7053) and MC-VC(S)- PABQ (an ADC linker) is connected. MC-VC(S)-PABQ-Tubulysin M is effective against multidrug-resistant lymphoma cell lines and tumors .
    MC-VC(S)-PABQ-Tubulysin M
  • HY-121588

    Adrenergic Receptor Cancer
    IMTPPE is an inhibitor of the androgen receptor (AR) in C4-2 prostate cancer cells, inhibiting its transcriptional activity and protein levels. IMTPPE inhibited the proliferation of AR-positive prostate cancer cells but had no effect on AR-negative prostate cancer cells. IMTPPE also inhibited the growth of enzalutamide-resistant 22Rv1 xenograft tumors .
    IMTPPE
  • HY-160053

    PDGFR Cancer
    Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment .
    Gint4.T aptamer sodium
  • HY-153342
    Luxdegalutamide
    1 Publications Verification

    ARV-766

    PROTACs Androgen Receptor Cancer
    Luxdegalutamide (ARV-766) is an orally active protein hydrolysis targeted chimeric (PROTAC) targeting androgen receptor (AR), which can degrade AR resistance related mutants, including T878/H875/L702 mutants. Luxdegalutamide has anti-tumor activity and can be used in the study of castration resistant prostate cancer .
    Luxdegalutamide
  • HY-15794
    Nemorubicin
    1 Publications Verification

    Methoxymorpholinyl doxorubicin; FCE 23762; PNU 152243

    G-quadruplex Cancer
    Nemorubicin (Methoxymorpholinyl doxorubicin) is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .
    Nemorubicin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: